아시아 태평양 미세 침습성 녹내장 수술(MIGS) 장치 시장 – 2029년까지의 산업 동향 및 예측

아시아 태평양 미세 침습성 녹내장 수술(MIGS) 장치 시장 분석 및 규모

미세 침습성 녹내장 수술은 개방각 녹내장을 치료하는 데 사용됩니다. 처음에는 OAG를 치료하기 위해 방수 생성을 줄이거나 방수 유출을 늘리는 약물을 투여했습니다. 경증에서 중등도의 OAG의 경우 전통적으로 약물 치료와 레이저 치료를 시행했습니다. 미세 침습성 녹내장 수술(MIGS) 시술이 등장하면서 기존 수술에 적합하지 않은 사람들을 위한 새로운 옵션이 만들어졌습니다. 노인 인구가 증가하고 실명을 예방하기 위한 정부 이니셔티브가 증가함에 따라 시장이 활성화될 것으로 예상됩니다. 녹내장 약물에서 최소 침습성 녹내장 수술로의 빠른 전환은 MIGS 장치 제조업체에 기회를 창출할 수 있습니다. 그러나 환불 시설이 부족하면 시장에 장애물이 될 수 있습니다.

미세 침습 수술에 대한 수요 증가는 눈 질환의 증가, 미세 침습 수술에 대한 수요 증가, 수술적 외상 감소로 인해 예측 기간 동안 시장에 대한 수요가 증가했기 때문입니다. 그러나 높은 설치 비용과 숙련된 전문가의 부족은 예측 기간 동안 최소 침습 수술 시장 성장을 방해할 수 있습니다.

Data Bridge Market Research는 미세 침습성 녹내장 수술(MIGS) 장치 시장이 2029년까지 7억 8,704만 달러 규모에 도달할 것으로 예상하고 있으며, 예측 기간 동안 CAGR은 30.6%입니다. "MIGS 스텐트"는 미세 침습성 녹내장 수술(MIGS) 장치 사용을 상용화하기 위한 기술 경로의 빠른 발전으로 인해 미세 침습성 녹내장 수술(MIGS) 장치 시장에서 가장 큰 기술 부문을 차지합니다. 미세 침습성 녹내장 수술(MIGS) 장치 시장 보고서는 또한 심층적인 기술 발전을 다룹니다.         

Market Definition

MIGS stands for micro invasive glaucoma surgery, which helps treat glaucoma. It is a breakthrough technology in the treatment of mild to moderate glaucoma. It is an alternative to the medications given earlier, and it also prevents the complications of conventional surgery. These procedures are used to lower the intra-ocular pressure of the eye to avoid damage to the optic nerve. These procedures are safer and have a very rapid recovery time compared to conventional surgery. The various MIGS devices implanted are shunts and stents to lower the IOP.

Micro Invasive Glaucoma Surgery (MIGS) Devices Market Dynamics

• Increase in the geriatric population

A significant health-related issue among the elderly is vision loss. According to the American Academy of Family Physicians, by age 65, one in three people suffer from vision-reducing eye disease. The elderly population is increasing rapidly. Therefore this creates a demand for advanced  technologies to treat glaucoma amongst older adults. Hence, an increase in the geriatric population is a driver for the market.

• Rise in incidence of glaucoma across the world

The cause of irreversible global blindness is majorly glaucoma. A glaucoma is a group of eye disorders that have very little to no symptoms in the initial stage but afterward lead to damage of optic nerves, which can lead to vision loss or blindness. The prevalence of glaucoma has been increasing. Therefore this creates a demand for MIGS devices; hence an increasing incidence of glaucoma is expected to act as a driver for the market.

• Government initiatives to increase awareness about the prevention of blindness

According to WHO, at least 2.2 billion people have visual impairment and blindness, out of which at least 1 billion have a vision impairment that could have been prevented. To prevent these, the government of several countries across the globe have taken initiatives. This creates a demand for advanced treatments such as micro-invasive glaucoma surgery, which boosts the MIGS device market. Hence, it is expected to act as a driver for the market.

• Introduction of technological advanced product 

Glaucoma is a severe eye disease that can lead to vision loss if not controlled. It generally does not lead to blindness as it can be controlled by modern treatment and many options for preventing further damage. With the increased scientific developments, there has been a revolutionary change in the treatment of glaucoma. With the advent of micro-invasive glaucoma surgery, there is a paradigm shift in medicine as it can help in the treatment of glaucoma at an early stage and avoid the dependency on filtration surgeries like trabeculectomy. This also overcomes the risks associated with these incisional surgeries. There are various advancements in the treatment of glaucoma with MIGS.

Restraints/Challenges faced by the Market

• Stringent regulations for MIGS devices

There are at least 7 regulations that any device manufacturer must completely fulfill in the U.S., namely Establishment Registration & Medical Device Listing, Premarket Notification 510(k), Premarket Approval (PMA)(only for class three devices), Investigational Device Exemption (IDE) for clinical studies, Quality System (QS) regulation, Labeling requirements, and Medical Device Reporting (MDR). These highest-risk devices need a more stringent premarket application regulatory process to demonstrate valid evidence of safety and efficacy. Lengthy timelines result in delayed access, which might restrict the market for MIGS devices.

• High cost of surgical procedures

Though glaucoma treatments have modest results and are safer than traditional filtration surgeries, they have very high costs. Also, people may require subsequent surgeries if the intra-ocular pressure is not effectively lowered at once. All these considerations make these procedures highly costly and inaccessible to most people and hence, high surgical procedure costs might be a restraint on the market.

Recent Developments

• In January 2022, Glaukos announced GLK=301's first patient enrolment in the Phase II clinical trial for dry eye disease. After the successful approval from the regulatory body, this drug will help the company grow its business segment.
• In January 2022, Alcon acquired Ivantis, developer of the novel Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device. This surgical device is designed to lower eye pressure for open-angle glaucoma patients. This acquisition will enhance the company’s portfolio in eye surgery segment.

Micro Invasive Glaucoma Surgery (MIGS) Devices Market Scope

The micro invasive glaucoma surgery (MIGS) devices market is segmented on the basis of product, target, surgery, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• MIGS stents
• MIGS shunts
• Others

On the basis of product, the micro invasive glaucoma surgery (MIGS) devices market is segmented into MIGS shunts, MIGS stents, and others.

Target

• Trabecular meshwork
• Suprachoroidal space
• Subconjunctival filtration
• Reducing aqueous production

On the basis of target, the micro invasive glaucoma surgery (MIGS) devices market is segmented into the trabecular meshwork, suprachoroidal space, subconjunctival filtration, and reducing aqueous production.

Surgery

• Glaucoma in conjunction with cataract
• Stand-alone glaucoma

On the basis of surgery, the micro invasive glaucoma surgery (MIGS) devices market is segmented into glaucoma in conjunction with cataract and stand-alone glaucoma.

End User

• Hospital outpatient departments (HOPD)
• Ophthalmology clinics
• Ambulatory surgery centers (ASCS)
• Others

On the basis of end-user, the micro invasive glaucoma surgery (MIGS) devices market is segmented into hospital outpatient departments (HOPD), ophthalmology clinics, ambulatory surgery centers (ASCS), and others.

Distribution Channel

• Direct tender
• Retail sales

On the basis of distribution channel, the micro invasive glaucoma surgery (MIGS) devices market is segmented into direct tender and retail sales.

Micro Invasive Glaucoma Surgery (MIGS) Devices Market Regional Analysis/Insights

The micro invasive glaucoma surgery (MIGS) devices market is analysed and market size insights and trends are provided by country, product, target, surgery, end user, and distribution channel as referenced above.

The countries covered in the micro invasive glaucoma surgery (MIGS) devices market report are China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines and Rest of Asia-Pacific.  

China dominates the Asia-Pacific micro invasive glaucoma surgery (MIGS) devices market. The demand in this region is projected to be driven by market players who are focusing on expanding their regional product offerings and enhancing their presence in emerging markets through various growth strategies, such as, expansions, partnerships, and collaborations among others.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Micro Invasive Glaucoma Surgery (MIGS) Devices Market Share Analysis

미세 침습성 녹내장 수술(MIGS) 장치 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 지역적 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 미세 침습성 녹내장 수술(MIGS) 장치 시장에 대한 회사의 초점과만 관련이 있습니다.

미세 침습적 녹내장 수술(MIGS) 장비 시장의 주요 기업으로는 AbbVie, BVI, Ellex, Glaukos Corporation, Johnson and Johnson, Alcon, Microsurgical technology, New World Medical, Santen Pharmaceutical, Nova Eye Medical Limited, Belkin Vision, Sight Scientific 등이 있습니다.

SKU-53733